Literature DB >> 33847020

Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue.

Theoharis C Theoharides1,2,3,4,5, Christos Cholevas5, Konstantinos Polyzoidis5, Antonios Politis6.   

Abstract

COVID-19 leads to severe respiratory problems, but also to long-COVID syndrome associated primarily with cognitive dysfunction and fatigue. Long-COVID syndrome symptoms, especially brain fog, are similar to those experienced by patients undertaking or following chemotherapy for cancer (chemofog or chemobrain), as well in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) or mast cell activation syndrome (MCAS). The pathogenesis of brain fog in these illnesses is presently unknown but may involve neuroinflammation via mast cells stimulated by pathogenic and stress stimuli to release mediators that activate microglia and lead to inflammation in the hypothalamus. These processes could be mitigated by phytosomal formulation (in olive pomace oil) of the natural flavonoid luteolin.
© 2021 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  COVID-19; brain fog; chemotherapy; coronavirus; cytokines; fatigue; inflammation; mast cells; microglia

Year:  2021        PMID: 33847020     DOI: 10.1002/biof.1726

Source DB:  PubMed          Journal:  Biofactors        ISSN: 0951-6433            Impact factor:   6.113


  18 in total

Review 1.  Controlling the Burden of COVID-19 by Manipulating Host Metabolism.

Authors:  Logan Miller; Engin Berber; Deepak Sumbria; Barry T Rouse
Journal:  Viral Immunol       Date:  2021-12-13       Impact factor: 2.257

Review 2.  [Physical long-term consequences of cancer].

Authors:  Lisa Ernst; Georgia Schilling
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-03-21       Impact factor: 1.513

3.  Neurological Involvement in COVID-19 Among Non-Hospitalized Adolescents and Young Adults.

Authors:  Lise Beier Havdal; Lise Lund Berven; Joel Selvakumar; Tonje Stiansen-Sonerud; Truls Michael Leegaard; Trygve Tjade; Henrik Zetterberg; Kaj Blennow; Vegard Bruun Bratholm Wyller
Journal:  Front Neurol       Date:  2022-06-22       Impact factor: 4.086

Review 4.  Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis.

Authors:  Lavienraj Premraj; Nivedha V Kannapadi; Jack Briggs; Stella M Seal; Denise Battaglini; Jonathon Fanning; Jacky Suen; Chiara Robba; John Fraser; Sung-Min Cho
Journal:  J Neurol Sci       Date:  2022-01-29       Impact factor: 3.181

Review 5.  Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?

Authors:  Theoharis C Theoharides
Journal:  Mol Neurobiol       Date:  2022-01-13       Impact factor: 5.682

6.  Long COVID syndrome-associated brain fog.

Authors:  Ali A Asadi-Pooya; Ali Akbari; Amir Emami; Mehrzad Lotfi; Mahtab Rostamihosseinkhani; Hamid Nemati; Zohreh Barzegar; Maryam Kabiri; Zahra Zeraatpisheh; Mohsen Farjoud-Kouhanjani; Anahita Jafari; Sarvin Sasannia; Shayan Ashrafi; Masoume Nazeri; Sara Nasiri; Mina Shahisavandi
Journal:  J Med Virol       Date:  2021-10-24       Impact factor: 20.693

Review 7.  Long COVID and oral health care considerations.

Authors:  Katherine France; Michael Glick
Journal:  J Am Dent Assoc       Date:  2021-10-29       Impact factor: 3.454

Review 8.  Regulation of Inflammatory Reaction in Health and Disease.

Authors:  Massimo Fioranelli; Maria Grazia Roccia; Dana Flavin; Linda Cota
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

Review 9.  Potential Therapeutic Use of the Rosemary Diterpene Carnosic Acid for Alzheimer's Disease, Parkinson's Disease, and Long-COVID through NRF2 Activation to Counteract the NLRP3 Inflammasome.

Authors:  Takumi Satoh; Dorit Trudler; Chang-Ki Oh; Stuart A Lipton
Journal:  Antioxidants (Basel)       Date:  2022-01-06

10.  A Practical Strategy for Exploring the Pharmacological Mechanism of Luteolin Against COVID-19/Asthma Comorbidity: Findings of System Pharmacology and Bioinformatics Analysis.

Authors:  Yi-Zi Xie; Chen-Wen Peng; Zu-Qing Su; Hui-Ting Huang; Xiao-Hong Liu; Shao-Feng Zhan; Xiu-Fang Huang
Journal:  Front Immunol       Date:  2022-01-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.